Aeterna Zentaris Inc.

Equities

AEZS

CA0079755017

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 02:29:06 2024-04-25 pm EDT			5-day change	1st Jan Change
2.66 ^CAD	0.00%		-0.37%	+3.50%

Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ
Mar. 28	Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	MT

Aeterna Zentaris : to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014

July 31, 2014 at 07:31 am EDT

QUEBEC CITY, July 31, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its second quarter 2014 financial and operating results after market close on Thursday, August 7, 2014. The Company will host a conference call to discuss these results on Friday, August 8, 2014, at 8:30 a.m. eastern time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Newsroom" section, or by telephone using the following numbers: in Canada, 514-807-9895 or 647?427?7450, outside Canada, 888-231-8191. A replay of the webcast will also be available on the Company's website for a period of 30 days.

About Aeterna Zentaris

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company's pipeline encompasses compounds at various stages of development. For more information, visit www.aezsinc.com.

SOURCE Aeterna Zentaris Inc.

Latest news about Aeterna Zentaris Inc.

North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	Mar. 28	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	Mar. 28	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	Mar. 27	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	Mar. 27	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	Mar. 27	MT
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	Feb. 26	MT
Traders Search for Fresh Cues After Fed-Driven Rally as US Equity Futures Waver Pre-Bell	Dec. 18	MT
Top Premarket Gainers	Dec. 18	MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	Dec. 14	MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	Dec. 14	MT
Aeterna Zentaris Inc. entered into a definitive agreement to acquire Ceapro Inc. for CAD 20 million in a merger of equals transaction.	Nov. 28	CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	Nov. 16	DJ
HC Wainwright Cuts Aeterna Zentaris' Price Target to $15 From $28, Maintains Buy Rating	Nov. 13	MT
Aeterna Zentaris Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ
North American Morning Briefing : China Angst -2-	23-08-15	DJ
Aeterna Zentaris Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Aeterna Zentaris Brief: Ended Q2 with US$42.2 million in cash, expected to fund operations into 2025	23-08-09	MT
Aeterna Zentaris Brief: Reported a Q2 consolidated net loss of US$2.5 million, or $0.52 loss per common share (basic and diluted)	23-08-09	MT
Transcript : Aeterna Zentaris Inc. - Special Call	23-07-13
Aeterna Zentaris Outlines "Progress" on Development Pipeline Programs and Providies Corporate Update	23-07-13	MT

Chart Aeterna Zentaris Inc.

Duration

Period

More charts

Company Profile

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
AETERNA ZENTARIS INC.	+3.50%	9.41M
IQVIA HOLDINGS INC.	+1.01%	43.84B
MODERNA, INC.	+6.26%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.43%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.38%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.95%	12.29B
MEDPACE HOLDINGS, INC.	+25.81%	12.29B
UNITED THERAPEUTICS CORPORATION	+6.86%	11.15B

Other Biotechnology & Medical Research

Aeterna Zentaris Inc.

Equities

AEZS

CA0079755017

Biotechnology & Medical Research

Aeterna Zentaris : to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014

Latest news about Aeterna Zentaris Inc.

Chart Aeterna Zentaris Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research